Antiepileptic drug monitoring: a reappraisal

Abstract

As clinical experience with the pharmacokinetic properties and optimal dosing of the established antiepileptic drugs (AEDs) has increased, frequent monitoring of AED concentration in the blood may be less necessary than it was 15 to 25 years ago. Monitoring continues to be valuable at initiation of treatment, addition or removal of other interacting drugs, at the time of unexpected seizure breakthrough, or when symptoms suggest AED toxicity. Occasional determination to monitor compliance may also be appropriate. Blood level determinations of certain of the new, less familiar AEDs, including felbamate, lamotrigine, and oxcarbazapine, appear to be useful. However, new approaches are needed to monitor the efficacy and possible toxicity of other new AEDs for which the correlation between blood concentration of AED and clinical outcome is less clear. For administration of these AEDs, including gabapentin, tiagabine, and vigabatrin, other indirect measures, such as determination of gamma-aminobutyric acid (GABA) levels in the cerebrospinal fluid or by nuclear magnetic resonance spectroscopy, may prove useful. For monitoring compliance, alternate technologies, such as a medication-dispensing vial with an electronic memory chip, may be of clinical value. In the clinical management of patients with epilepsy, blood level monitoring plays an important role, but methods of using this monitoring have evolved with increased experience and the introduction of AEDs with new mechanisms of action.